Bronchial Neoplasms: Clinical Trials

7,998 trials for Bronchial Neoplasms, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3096 completed, 1254 recruiting, 1193 unknown, 1039 terminated. 3621 Phase 2, 2239 Phase 1, 935 Phase 3, 726 Not applicable, 100 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 23621Completed 1352, Unknown 576, Recruiting 555, Terminated 502, Active not recruiting 266, Not yet recruiting 202, Withdrawn 149, Suspended 11, Enrolling by invitation 8
Phase 12239Completed 874, Terminated 437, Recruiting 396, Active not recruiting 201, Unknown 179, Withdrawn 76, Not yet recruiting 61, Suspended 11, Enrolling by invitation 4
Phase 3935Completed 359, Recruiting 143, Unknown 129, Active not recruiting 124, Terminated 114, Not yet recruiting 43, Withdrawn 18, Enrolling by invitation 3, Suspended 2
Not applicable726Completed 241, Unknown 139, Recruiting 137, Terminated 68, Not yet recruiting 60, Active not recruiting 40, Withdrawn 35, Enrolling by invitation 5, Suspended 1
Phase 4100Completed 47, Unknown 18, Recruiting 14, Terminated 9, Not yet recruiting 7, Active not recruiting 4, Suspended 1
Early Phase 164Completed 15, Terminated 11, Unknown 11, Recruiting 9, Not yet recruiting 8, Withdrawn 5, Enrolling by invitation 2, Suspended 2, Active not recruiting 1

Follow Bronchial Neoplasms: new trials by email Literature Review of Bronchial Neoplasms trials Research Report on Bronchial Neoplasms

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 Mutation
RC48-ADC, Pyrotinib - Non-small Cell Lung Cancer
Phase 1 / Phase 2Not yet recruitingRemeGen Co., Ltd.262027-12-012026-09-22
Multinational Observational Study to Describe Diagnostic Stage Shift in Patients With Lung Cancer Using Medical Records
Lung Cancer
Not yet recruitingAstraZeneca30002027-04-012026-06-02
A Phase 1a/1b Of Zanidatamab In Combination With Zongertinib In HER2-Mutated Non-Small Cell Lung Cancer (NSCLC)
Zanidatamab, Zongertinib - Non Small Cell Lung Cancer
Phase 1Not yet recruitingM.D. Anderson Cancer Center242027-04-012026-10-28
Moderately Hypofractionated Versus Conventional Chemoradiotherapy With Consolidation Immunotherapy in Patients With Unresectable, Non-Targetable Stage III Non Small Cell Lung Cancer (NSCLC)
Moderately Hypofractionated Radiotherapy, Conventionally Fractionated Radiotherapy - Stage III NSCLC
Not applicableNot yet recruitingTrans Tasman Radiation Oncology Group3002027-03-302026-11-06
Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
Atezolizumab, Atezolizumab and Recombinant Human Hyaluronidase, Biospecimen Collection - Lung Non-Small Cell Carcinoma
Phase 3RecruitingNational Cancer Institute (NCI)3362027-03-022026-11-05
Lung Functional Avoidance Radiotherapy Using Hyperpolarized Xenon MRI
Hyperpolarized xenon MRI - Carcinoma, Non-Small-Cell Lung
Phase 1 / Phase 2Not yet recruitingXemed LLC102027-03-012026-09-01
Using an Artificial Intelligence Software Tool (iSeg) During Radiation Treatment Planning for Patients With Lung Tumors
Artificial Intelligence-based Intervention, Best Practice, Computed Tomography - Lung Carcinoma, Lung Non-Small Cell Carcinoma
Not applicableNot yet recruitingNorthwestern University342027-02-132026-10-27
Cemiplimab for Clinical Stage I, 2-3.9cm, Non-Small Cell Lung Cancer
Cemiplimab, Pemetrexed (1), Cisplatin - Non-Small Cell Lung Cancer
Phase 2Not yet recruitingMedical University of South Carolina382027-02-012026-11-10
A Trial Evaluating the Anti-tumor Activity of Antibody-based Therapies in Metastatic Cancer Patients
Trastuzumab Deruxtecan for Injection (T-DXd) - NSCLC (Advanced Non-small Cell Lung Cancer), Urothelial Cancer
Phase 2Not yet recruitingCentre Leon Berard2002027-02-012026-11-13
DK222 Study at Hopkins
[18F]DK222 radiotracer - Non-Small Cell Lung Cancer, Urothelial Cancer
Phase 1RecruitingSidney Kimmel Comprehensive Cancer Center at Johns Hopkins62027-01-312026-09-29
Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC
Durvalumab 50 MG/1 ML Intravenous Solution, Etoposide Injection, Cisplatin - Extensive-stage Small-cell Lung Cancer
Phase 1SuspendedUniversity of Maryland, Baltimore502027-01-302026-09-14
Study Using a Drug-device Combination Product to Determine Safety, Tolerability and Antitumor Activity for Patients With Advanced, Non-small Cell Lung Cancer
NHT102, DryNeb - NSCLC (Advanced Non-small Cell Lung Cancer)
Phase 1 / Phase 2Not yet recruitingNob Hill Therapeutics, Inc.1002027-01-112026-10-08
A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants Previously Treated, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer
Telisotuzumab Adizutecan, Docetaxel, Ramucirumab - Non-Squamous Non-Small Cell Lung Cancer
Phase 3Not yet recruitingAbbVie6602027-01-062026-10-05
Effects of Supervised Aerobic Exercise on Biomarkers in Patients With nSCLC Receiving Immunotherapy
Exercise - Non-Small Cell Lung Cancer, Aerobic Exercise
Not applicableNot yet recruitingIzmir Bakircay University782027-01-042026-10-21
Lurbinectedin With Osimertinib in Transformed Small Cell Lung Cancer
Lurbinectedin, Osimertinib - Small Cell Lung Cancer ( SCLC ), Transformed Small Cell Lung Cancer
Phase 1 / Phase 2RecruitingMisty Shields162027-01-012026-10-15
Perioperative Cemiplimab for Resectable Non-Small Cell Lung Cancer With High PD-L1
Cemiplimab, Adjuvant chemotherapy - Lung Cancer (NSCLC)
Phase 2Not yet recruitingHenry Ford Health System332027-01-012026-07-15
Tarlatamab and Durvalumab vs. Durvalumab Alone for Limited-Stage-Small Cell Lung Cancer
Tarlatamab, Durvalumab - Limited Stage Small-Cell Lung Cancer
Phase 3Not yet recruitingPrECOG, LLC.4302027-01-012026-06-09
ctDNA-Guided Intraventricular Therapy for CNS Malignancies
CSF ctDNA-Guided Clinical Management - Leptomeningeal Disease, Glioblastoma
Not applicableNot yet recruitingAlireza Mansouri772027-01-012026-07-08
A Multicenter Randomized Open-Label Trial Evaluating ctDNA-Guided Interruption Versus Standard of Care Immune-Checkpoint Inhibitor (ICI) Therapy In Patients With Advanced / Metastatic Solid Tumors.
Signatera Genome ultra-sensitive ctDNA blood test - NSCLC (Advanced Non-small Cell Lung Cancer), NSCLC (Non-small Cell Lung Cancer)
Not applicableNot yet recruitingNatera, Inc.9202027-01-012026-10-27
Prospective Study on Radiation Induced Cardiotoxicity Assessed By PET-CT for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
PET/CT 18F-Flurpiridaz Rest/Stress Test, Coronary CT Angiography (CCTA), 18F-Flurpiridaz - Non Small Cell Lung Cancer, Cardiotoxicity
Phase 2RecruitingIndiana University102027-01-012026-11-10

Showing 20 of 7998. Sign in to see all of them.

Narrower conditions

Carcinoma, Non-Small-Cell Lung (7102)  ·  Lung Neoplasms (1919)  ·  Small Cell Lung Carcinoma (1207)  ·  Neoplasms (482)  ·  Colorectal Neoplasms (462)  ·  Melanoma (422)  ·  Breast Neoplasms (416)  ·  Neoplasm Metastasis (367)  ·  Ovarian Neoplasms (326)  ·  Squamous Cell Carcinoma of Head and Neck (302)  ·  Carcinoma, Renal Cell (299)  ·  Pancreatic Neoplasms (288)  ·  Stomach Neoplasms (255)  ·  Adenocarcinoma of Lung (238)  ·  Triple Negative Breast Neoplasms (214)

Broader conditions

Respiratory Tract Diseases (7957)  ·  Neoplasms by Site (7953)  ·  Respiratory Tract Neoplasms (7949)  ·  Thoracic Neoplasms (7939)  ·  Carcinoma, Bronchogenic (7924)  ·  Lung Diseases (7920)  ·  Neoplasms (7516)  ·  Lung Neoplasms (6079)  ·  Neoplasms by Histologic Type (1501)  ·  Neoplasms, Glandular and Epithelial (1290)  ·  Carcinoma (1047)  ·  Digestive System Diseases (881)  ·  Skin and Connective Tissue Diseases (870)  ·  Digestive System Neoplasms (868)

Interventions

Carboplatin (953)  ·  Cisplatin (660)  ·  Pemetrexed (639)  ·  Paclitaxel (526)  ·  pembrolizumab (506)  ·  Docetaxel (452)  ·  Gemcitabine (343)  ·  Erlotinib Hydrochloride (308)  ·  Radiotherapy (290)  ·  Nivolumab (271)  ·  Bevacizumab (244)  ·  Etoposide (213)  ·  durvalumab (207)  ·  Drug Therapy (193)  ·  osimertinib (187)

Sponsors

National Cancer Institute (NCI) (206)  ·  AstraZeneca (197)  ·  Eli Lilly and Company (152)  ·  Pfizer (130)  ·  M.D. Anderson Cancer Center (109)  ·  Sun Yat-sen University (102)  ·  Hoffmann-La Roche (101)  ·  Novartis Pharmaceuticals (100)  ·  Bristol-Myers Squibb (97)  ·  Merck Sharp & Dohme LLC (89)  ·  Boehringer Ingelheim (76)  ·  Memorial Sloan Kettering Cancer Center (76)  ·  Alliance for Clinical Trials in Oncology (70)  ·  GlaxoSmithKline (56)  ·  Shanghai Pulmonary Hospital, Shanghai, China (56)

Countries

United States (3606)  ·  China (1987)  ·  France (904)  ·  Spain (894)  ·  South Korea (732)  ·  Italy (722)  ·  Canada (701)  ·  Germany (642)  ·  United Kingdom (600)  ·  Australia (526)  ·  Taiwan (515)  ·  Japan (483)  ·  Belgium (452)  ·  Netherlands (446)  ·  Poland (431)

Results publications

PMID 27130468, PMID 37419867, PMID 40311309, PMID 22586319, PMID 23442309, PMID 27718847, PMID 34870327, PMID 37465924, PMID 42820295, PMID 19692680, PMID 25881079, PMID 26104945, PMID 26291008, PMID 26291023, PMID 27959700, PMID 29658848, PMID 30280641, PMID 33337539, PMID 35537408, PMID 38642841, PMID 39113428, PMID 39462179, PMID 25175099, PMID 25436806, PMID 25490004, PMID 25589191, PMID 26028407, PMID 26051236, PMID 26768165, PMID 26823294, PMID 28445469, PMID 28472437, PMID 28501139, PMID 28885881, PMID 29290251, PMID 29658856, PMID 30207593, PMID 30419929, PMID 31590988, PMID 32736936, PMID 33096027, PMID 33241650, PMID 34405547, PMID 34408488, PMID 34409776, PMID 35576956, PMID 35930972, PMID 36184621, PMID 37934000, PMID 38468440

NIH funding

2023 (134), 2017 (62), 2016 (59), 2018 (59), 2019 (58), 2025 (57), 2014 (49), 2015 (48), U10CA031946 (36), U10CA032102 (26), P30CA033572 (23), 2009 (21), U10CA180888 (21), 2008 (19), P30CA012197 (19)